Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.

出版年份 2020 全文链接

标题

作者

关键词

出版物

Volume 38, Issue 15_suppl, Pages 3640-3640

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2020-05-25

DOI

10.1200/jco.2020.38.15_suppl.3640

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started